Forum Replies Created
-
AuthorPosts
-
I have also recently purchased branded Olysio (simeprevir) from MTO Pharma. Prescription and identification was required and payment was made through Western Union. MTO Pharma were prompt in their responses to my questions and I found them to be punctual and courteous.
Parcel was sent through EMS (MTO provided a copy of the slip and tracking number) and was tracked on-line through the EMS website to its final delivery. Delivery took 9 days from dispatch, although it was delayed in Ukrainian customs for four days, but MTO were proactive in seeking its release from customs.
Branded Olysio is authentic and manufactured in Italy.
I concur with J.Eugene’s comments above.
5 April 2016 at 8:29 am in reply to: How long should I wait after treatment before getting pregnant #14911But if RBV is in the mix it would be significantly longer than six months! James, over to you on that one.
J,
Thanks for your kind words. I too wish you all the best and please keep me informed of your deliberations. I totally understand your view to wait before undertaking retreatment but I need to get on with my life and want to put this behind me as soon as possible. I firmly believe that this DAA regime will do the trick! I have attached a study (without RBV) which had some impressive results (albeit small sample size and some G1b’s) – hence my desire to start as soon as it is practical to do so – waiting, waiting, waiting…..
In respect of adding daclatasvir into the mix there is no doubt that its efficacy will be significantly reduced but it adds a little more potency into the therapy. It was actually a suggestion by Dr James Freeman and I discussed it with my gastroenterologist who is happy that I include it into the regimen. I thought that I may be able to get away with not having RBV but he also said that RBV does seem to impact on the emergence of resistance during therapy and that I should include to increase my chances (albeit minor) and continue for 24 weeks.
I will keep you informed of progress.Jonathan
Attachments:J,
It seems that you are in a very similar boat to me. Prior to treatment I had NS5A resistance at L30M and treatment emergent RAV’s at Q30R. Unfortunately, various studies suggest that NS5A treatment-emergent RAVs persist for a long period of time (but NS3 RAV’s disappear after 12 to 18 months) and obviously present a challenge for clinicians (and patients).
Your physician’s suggestion is consistent with the advice that I have been given from my gastroenterologist ie sofosbuvir/simeprevir plus ribavirin for 24 weeks. Retreatment with a different class of DAA, addition of RBV and treat for a longer period.
I am awaiting results for NS3 simeprevir resistance tests just to make sure prior to recommencing treatment. I would suggest that for peace of mind and prior to retreatment, you need to undertake testing for simeprevir resistance, in particular Q80K. You didn’t mention whether this had been undertaken in your post.
Notwithstanding, that I have NS5A resistance I will probably include daclatasvir into the DAA treatment regime and “throw everything but the kitchen sink at it” because I don’t want to go through another relapse and the detrimental psychological impact. It is a lot of treatment but better to be safe than sorry!
Jonathan
J. Eugene, I have not recommenced retreatment as yet but hopefully will do so within the next few weeks. I am awaiting the results of resistance studies, and a subsequent appointment with my gastroenterologist, before commencing retreatment.
Do you have any data on your baseline or treatment emergent RAV’s? That information is important because it will determine your retreatment options.
James,
My specialist has informed me that I could add daclatasvir to the treatment regimen but that its efficacy would be severely impaired due to pre-existing NS5A RAV’s (which include L31M and now Q30R following relapse after 12 weeks of elbasvir/grazoprevir in a clinical trial). He also stated that I need to add RBV and that treatment needs to be for 24 weeks which presents a major problem – I don’t have access to 24 weeks of simeprevir!
You mentioned in a previous post that you have some simeprevir available for retreatment purposes but it is expensive. My question is would I be able to access 12 weeks of simeprevir and what would the cost be to do so?
Thanks
James,
FYI – the attached presentation from AASLD conference in San Fransisco is of relevance to our discussion.
Cheers
James,
According to the DAA drug interaction charts ledipasvir/sofosbuvir should not be co-administered with simeprevir. However, sofosbuvir/daclatasvir/simeprevir can be co-administered. Any ideas as to why that may be the case?
Cheers
James,
For your information I was in a 12 week trial with Grazoprevir/Elbasvir about eighteen months ago. Although I was undetected at EOT (and for 8 weeks during the trial period) I relapsed about two weeks later. I was informed the reason being that I had NS5A RAV’s at baseline (L31M) and treatment emergent NS5A RAV’s (Q30R) – although I did not have any NS3 RAV’s at baseline or treatment emergent NS3 RAV’s (that they could ascertain from population sequencing).
My specialist has suggested a 12 week course of sofosbuvir/simeprevir/ribavirin – what are your thoughts? Any alternative options that may have greater efficacy?
I am GT1a, F1-F2.
-
AuthorPosts
